India Exchange Filings

Biocon Pertuzumab EU Marketing Authorization

Biocon Ltd secures European Commission marketing authorization for pertuzumab biosimilar Pebrilzo®

  • Authorized in the EU for HER2-positive breast cancer across multiple disease stages.
  • First biosimilar approved under the EMA’s new tailored clinical approach.
  • Follows recent U.S. FDA approval and adds to Biocon’s oncology biosimilar portfolio.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.